MSM for Exercise Recovery Remains Unproven

MSM is not proven to improve exercise recovery. Small human studies have found changes in gene expression and oxidative-stress markers, plus hints of less soreness, but the better-controlled trials have not shown a reliable improvement in recovery that athletes can feel or use.

The newer claim that benefits occur at “1 g/day” needs particular care. It comes from a 10-person biomarker study, not a trial showing less soreness, faster strength recovery or better subsequent performance. It also was not the dose used throughout the study: participants took 0.5 g daily for 27 days and 1 g daily for only the final three days.

What has actually been tested

Study	MSM protocol	What it measured	Result that matters
2025 half-marathon trial	0.5 g/day for 27 days, then 1 g/day for 3 days	Immune-related mRNA 2 and 4 hours after racing	29 mRNAs had post-race changes identified as unique to MSM; soreness, strength and performance recovery were not tested
2023 downhill-running trial	3 g/day for 30 days	Immune-related mRNA, soreness and creatine kinase	mRNA responses differed, but soreness and creatine kinase did not differ significantly
2017 half-marathon trial	3 g/day for 21 days before the race and 2 days after	Pain, oxidative-stress markers and muscle-damage markers	Pain differences favored MSM but were not statistically significant; no significant treatment effect occurred for any measured outcome
2017 eccentric-exercise trial	3 g/day for 28 days	Soreness, muscle function and oxidative-stress markers	Soreness and force recovery favored MSM numerically, but differences were not statistically significant
2012 resistance-exercise pilot	1.5 or 3 g/day for 28 days before exercise	Soreness, fatigue, antioxidant markers and knee-extension work	Some favorable trends and biomarker changes, but no placebo group and no improvement in work performed

These trials do not establish an effective recovery dose. They tested different exercises, populations and outcomes, and most enrolled very few people.

The 1 g claim is an inference from gene expression

In the 2025 randomized, double-blind trial, five experienced runners received OptiMSM and five received placebo before a half-marathon. Researchers examined immune-related mRNA in blood collected before the race and two and four hours afterward. They identified 29 mRNAs with post-race changes unique to the MSM group and organized them into pathways involving inflammation, myeloid immune cells, natural killer cells and Notch signaling (Nutrients trial).

That is evidence that the stepped MSM protocol may affect an early molecular response to prolonged running. It is not direct evidence of faster recovery. The study did not report whether runners felt less sore, regained strength sooner, returned to training earlier or performed better in a later session.

Nor can it show that 1 g daily is the effective dose. The runners received 1 g for only three days after 27 days at 0.5 g. There was no separate 0.5 g group, 1 g group or dose comparison. The result therefore applies to the full stepped protocol—not cleanly to “1 g/day.”

The supplier’s announcement moves from changed biomarkers to possible benefits such as support for muscle recovery, while emphasizing the formulation advantages of a smaller dose (Balchem announcement). A later page promoting the 1 g claim was explicitly labeled as paid Balchem content rather than independent editorial analysis (NutraIngredients promotional page). Those commercial descriptions are not additional clinical evidence.

Confidence should also be limited by the five-person groups. The authors acknowledged the small sample and called for a larger study. Balchem provided grants and in-kind support, and the lead author disclosed serving on the company’s scientific advisory board (trial disclosures). Industry support does not invalidate a result, but independent replication would make the finding more persuasive.

Trials of soreness, damage and strength remain inconclusive

A 2017 placebo-controlled trial enrolled 22 half-marathon runners: 11 took 3 g of MSM daily and 11 took placebo. No time-by-treatment result was statistically significant, including muscle pain, joint pain, creatine kinase, lactate dehydrogenase and two oxidative-stress markers. Pain scores favored MSM by amounts the researchers considered potentially noticeable, but the differences could not be distinguished from chance (2017 half-marathon trial).

The study had aimed for 32 completers based on its power calculation and finished with 22. Bergstrom Nutrition supplied the products and laboratory funding, and one author worked for the company during the study. A favorable pattern in an underpowered study can justify another trial, but it does not demonstrate that MSM works.

A separate double-blind study was larger: 40 physically active men took 3 g daily or placebo for 28 days before eccentric knee extensions. MSM was associated with roughly 15% to 20% less soreness and an earlier return to baseline isometric force, but neither difference was statistically significant. No other between-group differences were found (University of Memphis record and abstract). This is another suggestive pattern, not a confirmed recovery benefit.

The 2023 downhill-running experiment found changes in immune-related mRNA after 3 g daily for 30 days. Yet soreness and creatine kinase did not differ significantly from placebo. It included only 12 participants—five receiving MSM—and evaluated immune responses in blood exposed to lipopolysaccharide in the laboratory. That makes its main result mechanistic rather than proof of better recovery (2023 trial). Bergstrom funded that research as well.

The earliest dose-comparison pilot is weaker evidence. Eight men took either 1.5 or 3 g daily, with no placebo group. The 3 g group had favorable trends in soreness and fatigue and a change in one antioxidant-capacity measure, but knee-extension work did not improve. The authors called it a proof-of-concept study and recommended a larger placebo-controlled trial (2012 pilot).

Other small studies in untrained young men reported favorable oxidative-stress or muscle-damage markers. For example, an 18-person placebo-controlled trial found lower post-run oxidative-stress markers after 10 days at 50 mg/kg/day (2011 trial abstract). Such results support further research into biological effects, but a changed blood marker does not by itself show less soreness, restored strength or readiness for another workout.

What the evidence supports—and what it does not

The defensible conclusion is narrow:

• Possible: MSM alters some inflammatory, immune or oxidative-stress responses after strenuous exercise.
• Uncertain: It modestly reduces perceived soreness or hastens strength recovery.
• Not established: It speeds return to training, reliably prevents muscle damage or improves later performance.
• Not established: 1 g daily is an effective recovery dose.
• Not established: OptiMSM works better than another adequately made MSM product. Trials using one branded ingredient cannot establish superiority without a direct comparison.

Anyone evaluating MSM should choose a practical outcome in advance—such as next-day soreness or restored training performance—rather than treating a cellular marker as proof of benefit. A single-ingredient product also makes attribution easier than a multi-ingredient recovery blend.

Our broader MSM evidence review explains how support differs by use. MSM dose limits and severity-based side-effect guidance address separate safety questions. For exercise recovery, the current evidence makes MSM an optional but unproven supplement, not a substitute for adequate food, fluids, sleep, rest or an appropriate training load.